Who owns RXRX?
Institutional ownership of Recursion Pharmaceuticals Inc. from Form 13F, Q2 2026
343 institutional managers reported holding Recursion Pharmaceuticals Inc. (RXRX) in Form 13F filings for Q2 2026, with 361,990,761 shares worth $1.3B. The largest reported holder was BlackRock, Inc. Managers that filed both quarters added a net 25,686,672 shares (+7.6%). 45 opened new positions and 41 sold out.
- Funds holding
- 343
- Value held
- $1.3B
- New / sold out
- 45 / 41
- Net shares, same filers
- +7.6%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of RXRX
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| BlackRock, Inc. | $185M | 13.9% | 50,304,691 | Added |
| ARK Investment Management LLC | $152M | 11.4% | 41,337,632 | Added |
| State Street Corp | $127M | 9.6% | 34,706,130 | Added |
| Vanguard Portfolio Management LLC | $114M | 8.6% | 31,131,599 | Added |
| Baillie Gifford & Co | $86.2M | 6.5% | 23,487,907 | Trimmed |
| Vanguard Capital Management LLC | $83.6M | 6.3% | 22,765,940 | Added |
| Geode Capital Management, LLC | $50.7M | 3.8% | 13,819,135 | Added |
| Softbank Group Corp. | $50.0M | 3.8% | 13,636,515 | Unchanged |
| MIC Capital Management UK LLP | $35.4M | 2.7% | 9,644,033 | Unchanged |
| UBS Group AG | $32.8M | 2.5% | 8,947,102 | Added |
| Norges Bank | $25.1M | 1.9% | 6,833,534 | New |
| Data Collective IV GP, LLC | $21.8M | 1.6% | 5,941,120 | Unchanged |
| Amova Asset Management Americas, Inc. | $20.2M | 1.5% | 5,511,687 | Added |
| Sumitomo Mitsui Trust Group, Inc. | $20.2M | 1.5% | 5,511,687 | Added |
| Northern Trust Corp | $17.5M | 1.3% | 4,758,236 | Added |
| Marshall Wace, LLP | $17.3M | 1.3% | 4,714,577 | Added |
| Charles Schwab Investment Management Inc | $15.2M | 1.1% | 4,138,286 | Added |
| DCVC Opportunity Fund II GP, LLC | $14.5M | 1.1% | 3,951,141 | Unchanged |
| Goldman Sachs Group Inc | $14.4M | 1.1% | 3,917,858 | Trimmed |
| Vanguard Fiduciary Trust Co | $12.7M | 1.0% | 3,470,558 | Trimmed |
| Two Sigma Investments, LP | $12.3M | 0.9% | 3,353,658 | Trimmed |
| Susquehanna International Group, LLP | $12.1M | 0.9% | 3,292,128 | Trimmed |
| First Trust Advisors LP | $11.2M | 0.8% | 3,041,829 | Added |
| Morgan Stanley | $10.1M | 0.8% | 2,743,499 | Added |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $9.6M | 0.7% | 2,604,317 | Added |
Share of 13F holdings is each fund's shares as a share of the 361,990,761 RXRX shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Vanguard Portfolio Management LLC Added+$30.7M
- BlackRock, Inc. Added+$26.1M
- Norges Bank New+$25.1M
- State Street Corp Added+$22.8M
- UBS Group AG Added+$14.1M
- Marshall Wace, LLP Added+$6.7M
- Geode Capital Management, LLC Added+$5.7M
- ARK Investment Management LLC Added+$4.1M
- Quadrature Capital Ltd New+$3.6M
- Northern Trust Corp Added+$2.9M
Biggest sellers in Q2 2026
- Lingotto Investment Management LLP Trimmed-$13.5M
- UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trimmed-$12.0M
- Goldman Sachs Group Inc Trimmed-$7.9M
- Renaissance Technologies LLC Sold out-$7.4M
- Capital Fund Management S.a. Sold out-$5.9M
- Susquehanna International Group, LLP Trimmed-$3.4M
- Millennium Management LLC Trimmed-$2.9M
- Mitsubishi UFJ Trust & Banking Corp Sold out-$2.8M
- Two Sigma Investments, LP Trimmed-$2.6M
- FMR LLC Trimmed-$2.5M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $181M and sold $83.0M; 126 added and 99 trimmed.
Schedule 13D and 13G filings on RXRX
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.Schedule 13G
- 2026-05-12STATE STREET CORP SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.Schedule 13G
Questions about RXRX ownership
- Who owns RXRX stock?
- 343 institutional investment managers reported RXRX positions in their Form 13F filings for Q2 2026, holding 361,990,761 shares worth $1.3B in total. BlackRock, Inc. reported the largest position.
- Are funds buying or selling RXRX?
- In Q2 2026, 45 managers opened new RXRX positions, 126 added, 99 trimmed and 41 sold out. Managers that filed in both quarters added a net 25,686,672 shares.
- How current is this RXRX institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to RXRX by CUSIP. Options are left out. RXRX news and filings · RXRX insider trades · Top funds